$PRTA
PROTHENA CORP PUBLIC LTD CO

2013 Q1 Form 10-Q Financial Statement

#000119312513220259 Filed on May 15, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q1
Revenue $171.0K $400.0K
YoY Change -57.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.180M $2.460M
YoY Change 29.27%
% of Gross Profit
Research & Development $5.957M $8.757M
YoY Change -31.97%
% of Gross Profit
Depreciation & Amortization $137.0K $113.0K
YoY Change 21.24%
% of Gross Profit
Operating Expenses $9.138M $11.22M
YoY Change -18.52%
Operating Profit -$8.967M -$10.81M
YoY Change -17.06%
Interest Expense $20.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $22.00K
YoY Change
Pretax Income -$8.945M -$10.81M
YoY Change -17.26%
Income Tax $6.000K $0.00
% Of Pretax Income
Net Earnings -$8.951M -$10.81M
YoY Change -17.2%
Net Earnings / Revenue -5234.5% -2702.75%
Basic Earnings Per Share -$0.51
Diluted Earnings Per Share -$0.51 -$745.5K
COMMON SHARES
Basic Shares Outstanding 17.68M shares
Diluted Shares Outstanding 17.68M shares

Balance Sheet

Concept 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $119.6M
YoY Change
Cash & Equivalents $119.6M
Short-Term Investments
Other Short-Term Assets $1.000M
YoY Change
Inventory
Prepaid Expenses
Receivables $300.0K
Other Receivables $0.00
Total Short-Term Assets $120.8M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $3.371M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K
YoY Change
Total Long-Term Assets $3.477M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $120.8M
Total Long-Term Assets $3.477M
Total Assets $124.3M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $3.400M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.086M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.400M
YoY Change
Total Long-Term Liabilities $1.400M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.086M
Total Long-Term Liabilities $1.400M
Total Liabilities $6.479M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$9.296M
YoY Change
Common Stock $177.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $117.8M
YoY Change
Total Liabilities & Shareholders Equity $124.3M
YoY Change

Cashflow Statement

Concept 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$8.951M -$10.81M
YoY Change -17.2%
Depreciation, Depletion And Amortization $137.0K $113.0K
YoY Change 21.24%
Cash From Operating Activities -$5.103M -$8.624M
YoY Change -40.83%
INVESTING ACTIVITIES
Capital Expenditures $110.0K $137.0K
YoY Change -19.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$110.0K -$137.0K
YoY Change -19.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$84.00K 8.761M
YoY Change -100.96%
NET CHANGE
Cash From Operating Activities -$5.103M -8.624M
Cash From Investing Activities -$110.0K -137.0K
Cash From Financing Activities -$84.00K 8.761M
Net Change In Cash -$5.297M 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$5.103M -$8.624M
Capital Expenditures $110.0K $137.0K
Free Cash Flow -$5.213M -$8.761M
YoY Change -40.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17679182 shares
CY2013Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1221000
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
822000
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5086000
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
894000
CY2013Q1 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
62000
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9296000
CY2013Q1 us-gaap Assets
Assets
124268000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
119563000
CY2013Q1 us-gaap Finite Lived Computer Software Gross
FiniteLivedComputerSoftwareGross
85000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
21000
CY2013Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7210000
CY2013Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
72000
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124268000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17679000 shares
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
177000
CY2013Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1393000
CY2013Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
41000
CY2013Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2418000
CY2013Q1 us-gaap Liabilities
Liabilities
6479000
CY2013Q1 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1513000
CY2013Q1 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
73000
CY2013Q1 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
375000
CY2013Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
5697000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
16000
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3371000
CY2013Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
261000
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17679000 shares
CY2013Q1 us-gaap Assets Current
AssetsCurrent
120791000
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126908000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
7000
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3839000
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
117789000
CY2013Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44000
CY2013Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
3477000
CY2013Q1 prta Deferred Shares Value
DeferredSharesValue
CY2013Q1 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2013Q1 prta Deferred Shares Share Issued
DeferredSharesShareIssued
shares
CY2013Q1 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
shares
CY2013Q1 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000000 shares
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2596000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
27000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1592000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1744000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
685000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345000
CY2012Q4 us-gaap Assets
Assets
129283000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124860000
CY2012Q4 us-gaap Finite Lived Computer Software Gross
FiniteLivedComputerSoftwareGross
85000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7100000
CY2012Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
27000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129283000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17679000 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
177000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1055000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
36000
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1670000
CY2012Q4 us-gaap Liabilities
Liabilities
2799000
CY2012Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1651000
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
73000
CY2012Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
51000
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
5449000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3393000
CY2012Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
223000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17679000 shares
CY2012Q4 us-gaap Assets Current
AssetsCurrent
125841000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126652000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3707000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
126484000
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
49000
CY2012Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
3442000
CY2012Q4 prta Deferred Shares Value
DeferredSharesValue
CY2012Q4 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2012Q4 prta Deferred Shares Share Issued
DeferredSharesShareIssued
shares
CY2012Q4 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
shares
CY2012Q4 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000000 shares
CY2012Q4 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
47000
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001559053
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 dei Trading Symbol
TradingSymbol
PRTA
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
Prothena Corp plc
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
137000
CY2013Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
271000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-110000
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
22000
CY2013Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
23000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5957000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8945000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17679000 shares
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
340000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5297000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8967000
CY2013Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Description of Business</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Prothena Corporation plc (&#x201C;Prothena,&#x201D; the &#x201C;Company,&#x201D; &#x201C;we,&#x201D; &#x201C;our&#x201D; or &#x201C;us&#x201D;), a public limited company incorporated in Ireland, is a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion. The Company is focused on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease causing proteins. These potential therapies have a broad range of indications including AL and AA forms of amyloidosis (NEOD001), Parkinson&#x2019;s disease and related synucleinopathies (PRX002) and autoimmune diseases and metastatic cancers (PRX003). The Company has initiated a Phase 1 clinical trial for NEOD001 with the first patient dosing in April 2013. The Phase 1 clinical trial of NEOD001 will evaluate safety and tolerability in AL Amyloidosis patients. The Company&#x2019;s strategy is to identify antibody candidates for clinical development by applying its extensive expertise in generating novel therapeutic antibodies and working with collaborators having expertise in specific animal models of disease.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Prothena&#x2019;s business consists of a substantial portion of Elan Corporation plc&#x2019;s (&#x201C;Elan&#x201D;) former drug discovery business platform, including Neotope Biosciences Limited (and its wholly-owned subsidiary Prothena Biosciences Inc) and Onclave Therapeutics Limited, each former wholly-owned subsidiaries of Elan (which for the period prior to separation and distribution are referred to herein as the &#x201C;Prothena Business&#x201D;). Effective December&#xA0;20, 2012, the Prothena Business separated from Elan.</font></p> </div>
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-8951000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3181000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-84000
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
38000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
9138000
CY2013Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P4Y
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3680000
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
110000
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5000
CY2013Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
171000
CY2013Q1 us-gaap Depreciation
Depreciation
100000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1366000 shares
CY2013Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of the Condensed Consolidated Financial Statements in conformity with generally accepted accounting principles in the United States (&#x201C;GAAP&#x201D;) requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</font></p> </div>
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5103000
CY2013Q1 prta Centralized Support Cost
CentralizedSupportCost
2000000
CY2013Q1 prta Post Separation Adjustments To Funding Provided By Related Party
PostSeparationAdjustmentsToFundingProvidedByRelatedParty
84000
CY2012Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
8761000
CY2012Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
113000
CY2012Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
32000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-137000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8757000
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10811000
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14497000 shares
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3570000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10811000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-10811000
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2458000
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8761000
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
11215000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1464000
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
137000
CY2012Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5000
CY2012Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
404000
CY2012Q1 us-gaap Depreciation
Depreciation
100000
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
476000
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1501000 shares
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8624000

Files In Submission

Name View Source Status
0001193125-13-220259-index-headers.html Edgar Link pending
0001193125-13-220259-index.html Edgar Link pending
0001193125-13-220259.txt Edgar Link pending
0001193125-13-220259-xbrl.zip Edgar Link pending
d507555d10q.htm Edgar Link pending
d507555dex311.htm Edgar Link pending
d507555dex312.htm Edgar Link pending
d507555dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
prta-20130331.xml Edgar Link completed
prta-20130331.xsd Edgar Link pending
prta-20130331_cal.xml Edgar Link unprocessable
prta-20130331_def.xml Edgar Link unprocessable
prta-20130331_lab.xml Edgar Link unprocessable
prta-20130331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending